Juan Bergua
109 Papers
260 Citations
Juan Bergua is an academic researcher. The author has contributed to research in topics: Medicine & Acute promyelocytic leukemia. The author has an hindex of 26, co-authored 90 publications.
Chat about Author
Papers
Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience
Jose A. Rodriguez,Eulogio Conde,Antonio Gutierrez,Reyes Arranz,Marcos Gandarillas,Angel Leon,Jesus Ojanguren,Anna Sureda,Dolores Carrera,Mauricio Bendandi,José M. Moraleda,Jose Maria Ribera,Carmen Albo,Alfonso Morales,Juan Carlos Camargo García,Pascual Fernández,Guillermo Cañigral,Juan Bergua,Maria Dolores Caballero +18 more
TL;DR: The experiences with 19 patients treated with high‐dose chemotherapy and autologous stem cell transplantation within the GELTAMO co‐operative group between 1992 and 2004 are reported.
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Christian Recher,Christoph Röllig,Emilie Bérard,Sarah Bertoli,Pierre-Yves Dumas,Suzanne Tavitian,Michael Kramer,Hubert Serve,Martin Bornhäuser,Uwe Platzbecker,Carsten Müller-Tidow,Claudia D. Baldus,David Martínez-Cuadrón,Josefina Serrano,Pilar Martínez-Sánchez,Eduardo Rodriguez Arbolí,Cristina Gil,Juan Bergua,Teresa Bernal,Adolfo de la Fuente Burguera,Eric Delabesse,Audrey Bidet,Arnaud Pigneux,Pau Montesinos +23 more
TL;DR: In this article, the authors compared the effect of intensive chemotherapy and hypomethylating agents on the overall survival of acute myeloid leukemia patients aged 70 years or older.
45
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
David Martínez-Cuadrón,David Martínez-Cuadrón,Blanca Boluda,Pilar Rodríguez Martínez,Juan Bergua,Rebeca Rodríguez-Veiga,Jordi Esteve,Susana Vives,Josefina Serrano,Belén Vidriales,Olga Salamero,Lourdes Cordón,Lourdes Cordón,Amparo Sempere,Amparo Sempere,Ana Jiménez-Ubieto,Julio Prieto-Delgado,Marina Díaz-Beyá,Ana Garrido,Celina Benavente,José A. Pérez-Simón,Federico Moscardó,Miguel A. Sanz,Miguel A. Sanz,Miguel A. Sanz,Pau Montesinos,Pau Montesinos,Pethema groups +27 more
TL;DR: The name of Pau Montesinos was inadvertently presented as PauMontesinos Fernández in the original article.
Rituximab in CD20 positive multiple myeloma
TL;DR: In the letter of Moreau, the result of a small trial of the treatment with rituximab as a single agent in patients with multiple myeloma that expresses CD20 is reported, there is no benefit for the patients newly diagnosed or relapsed with CD20þ MM.
32